ct-1

CT-1 is a DNA minor groove ligand and causes p53-dependent breast cancer cell apoptosis.

CT-179 is a potent and selective inhibitor of oligodendrocyte transcription factor 2 (OLIG2), reduces tumor cell proliferation and induces apoptosis, and enhances efficacy when used in combination with radiotherapy and other agents, showing potential in the treatment of medulloblastoma and glioblastoma.

NCT-10b is a selective inhibitor of HDAC6.

ACT-1004-1239 is an orally active, selective, and potent CXCR7 antagonist with immune-modulatory and myelin-promoting effects. It can be used to study inflammatory demyelinating diseases.

ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.

Citric acid (Citro) is a weak organic tricarboxylic acid found in citrus fruits. Citric acid is a food additive and a natural preservative.

11β-HSD2-IN-1 (compound CDSN) serves as a potent inhibitor of 11β-HSD2, effectively hindering this enzyme from metabolizing Cholestane-3β,5α,6β-triol (CT) into carcinogenic androstenedione within cells. By inhibiting testosterone biosynthesis, 11β-HSD2-IN-1 suppresses the proliferation of MCF-7 cells. Additionally, this compound exhibits immunological activity and offers protection against viral infections.

Concanavalin A is a natural product, a phytoalexin (glycan-binding protein). Concanavalin A has antitumor activity and can also induce acute liver injury.

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.

Enzyme-IN-1 (compound 1), a peptide-based inhibitor of N-terminal nucleophile (Ntn) hydrolases, specifically targets and inhibits the chymotrypsin-like activity (CT-L) of the 20S proteasome. This compound may possess potential anti-inflammatory properties [1].

Firivumab (CT-P22; CT120), a human IgG1 monoclonal antibody targeting influenza A virus hemagglutinin (Anti-IAV HA), demonstrates neutralization capabilities against multiple strains including H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2, and H12N7. It has also shown to protect mice from the H1N1 virus [1] [2] [3].

Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1].

Pegdinetanib (BMS-844203; CT-322) is a selective inhibitor targeting VEGFR-2 (VEGFR), with dissociation constants (Kd) of 11 nM and 250 nM and half-maximal inhibitory concentrations (IC50) of 16 nM and 240 nM for human and murine VEGFR-2, respectively, and shows no affinity for VEGFR-1 or VEGFR-3, demonstrating antitumor activity [1].

SSI-4 is a Stearoyl CoA desaturase 1 (SCD1) inhibitor that can be labeled with carbon-11 (11C) for use as a ligand in small animal in vivo PET/CT imaging studies of SCD1 [1].

OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2 and holds potential for research on kidney fibrosis and chronic kidney disease [1].

Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologic malignancies [1].

Sigma-2 Radioligand 1 (compound 1) serves as a selective Sigma-2 ligand, demonstrating favorable biodistribution in mice and robust in vivo activity in rats. The [18F] modified version of Sigma-2 Radioligand 1 enhances the visualization of tumors in micro-PET/CT imaging by providing high tumor uptake and an impressive tumor-to-background ratio. Additionally, experiments confirm that this compound binds with high specificity to U87MG glioma xenografts [1].